AIMS/HYPOTHESIS: To further our understanding of antigen presentation by HLA class II molecules, we have examined the influence of HLA class II genotype on expression of autoantibodies to islet antigen-2 (IA-2A). METHODS: HLA class II genotype and IA-2A were determined within 3 months of diagnosis in 618 patients with type 1 diabetes (median age 11 years [range 0.7-20.9]). Antibodies to the juxtamembrane region of IA-2 were measured by a radiobinding assay in 481 of 484 IA-2A-positive patients. RESULTS: IA-2A prevalence was highest in patients carrying at least one HLA-DRB1*04-DQA1*0301 (385 of 450; 86%), DRB1*07-DQA1*(0201 or 0301) (58 of 64; 91%) or DRB1*09-DQA1*0301 haplotype (18 of 19; 95%). Multiple regression showed that IA-2A were strongly associated with the number of these haplotypes carried; only 69 of 132 (52%) patients carrying none of these haplotypes had IA-2A, compared with 322 of 391 (82%) patients with one and 93 of 95 (98%) with two of these haplotypes (p < 0.001). IA-2 juxtamembrane antibodies were less frequent in IA-2A-positive patients with one (35%) or two (36%) DRB1*03-DQB1*02 or DRB1*07-DQB1*02 haplotypes than in those negative for these haplotypes (52%) (p = 0.002), but showed an independent positive association with IA-2A level (p < 0.001). CONCLUSIONS/ INTERPRETATION: HLA class II alleles strongly influence the prevalence of IA-2A. The high IA-2A prevalence in patients carrying DRB1*04, DRB1*07 and DRB1*09 alleles in linkage disequilibrium with DQA1*0301 or the closely related DQA1*0201 suggests the humoral response to IA-2 may be driven by HLA-DQA1 genes.
AIMS/HYPOTHESIS: To further our understanding of antigen presentation by HLA class II molecules, we have examined the influence of HLA class II genotype on expression of autoantibodies to islet antigen-2 (IA-2A). METHODS:HLA class II genotype and IA-2A were determined within 3 months of diagnosis in 618 patients with type 1 diabetes (median age 11 years [range 0.7-20.9]). Antibodies to the juxtamembrane region of IA-2 were measured by a radiobinding assay in 481 of 484 IA-2A-positive patients. RESULTS: IA-2A prevalence was highest in patients carrying at least one HLA-DRB1*04-DQA1*0301 (385 of 450; 86%), DRB1*07-DQA1*(0201 or 0301) (58 of 64; 91%) or DRB1*09-DQA1*0301 haplotype (18 of 19; 95%). Multiple regression showed that IA-2A were strongly associated with the number of these haplotypes carried; only 69 of 132 (52%) patients carrying none of these haplotypes had IA-2A, compared with 322 of 391 (82%) patients with one and 93 of 95 (98%) with two of these haplotypes (p < 0.001). IA-2 juxtamembrane antibodies were less frequent in IA-2A-positive patients with one (35%) or two (36%) DRB1*03-DQB1*02 or DRB1*07-DQB1*02 haplotypes than in those negative for these haplotypes (52%) (p = 0.002), but showed an independent positive association with IA-2A level (p < 0.001). CONCLUSIONS/ INTERPRETATION:HLA class II alleles strongly influence the prevalence of IA-2A. The high IA-2A prevalence in patients carrying DRB1*04, DRB1*07 and DRB1*09 alleles in linkage disequilibrium with DQA1*0301 or the closely related DQA1*0201 suggests the humoral response to IA-2 may be driven by HLA-DQA1 genes.
Authors: E Kawasaki; Y Sera; N Fujita; M Yamauchi; M Ozaki; T Abe; K Yamakawa; S Uotani; H Takino; H Yamasaki; Y Yamaguchi; Y Uchigata; N Matsuura; K Eguchi Journal: J Autoimmun Date: 2001-12 Impact factor: 7.094
Authors: A Paul Lambert; Kathleen M Gillespie; Glenys Thomson; Heather J Cordell; John A Todd; Edwin A M Gale; Polly J Bingley Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: S Genovese; R Bonfanti; E Bazzigaluppi; V Lampasona; E Benazzi; E Bosi; G Chiumello; E Bonifacio Journal: Diabetologia Date: 1996-10 Impact factor: 10.122
Authors: L I Alves; E Davini; M R Correia; R T Fukui; R F Santos; M R Cunha; D M Rocha; W M G Volpini; M E R Silva Journal: J Clin Immunol Date: 2012-03-09 Impact factor: 8.317
Authors: Michael P Morran; Anna Casu; Vincent C Arena; Susan Pietropaolo; Ying-Jian Zhang; Leslie S Satin; Patrick Nelson; Gilbert S Omenn; Massimo Trucco; Dorothy J Becker; Massimo Pietropaolo Journal: Endocrinology Date: 2010-04-09 Impact factor: 4.736
Authors: Ana M Wägner; Angelo Santana; Marta Herńndez; Julia C Wiebe; Javier Nóvoa; Dídac Mauricio Journal: Diabetes Metab Res Rev Date: 2011-07 Impact factor: 4.876
Authors: Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato Journal: PLoS One Date: 2010-12-01 Impact factor: 3.240
Authors: Mary Helen Black; Jean M Lawrence; Catherine Pihoker; Lawrence M Dolan; Andrea Anderson; Beatriz Rodriguez; Santica M Marcovina; Elizabeth J Mayer-Davis; Giuseppina Imperatore; Dana Dabelea Journal: Pediatr Diabetes Date: 2012-08-23 Impact factor: 4.866
Authors: Janet M Wenzlau; Lisa M Frisch; Thomas J Gardner; Suparna Sarkar; John C Hutton; Howard W Davidson Journal: Curr Diab Rep Date: 2009-04 Impact factor: 4.810